NEW
Scapho

Scapho

secukinumab

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Secukinumab
Indications/Uses
Moderate to severe plaque psoriasis in patients ≥6 yr who are candidates for systemic therapy or phototherapy. Alone or in combination w/ methotrexate for active psoriatic arthritis in adults. Active ankylosing spondylitis (AS) in adults. Active non-radiographic axial spondyloarthritis (nr-axSpA) w/ objective signs of inflammation.
Dosage/Direction for Use
SC Plaque psoriasis Adult 300 mg (as two 150 mg inj) w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing. Ped ≥50 kg 150 mg (as one 150 mg inj) w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance (every 4 wk), may be increased to 300 mg (as two 150 mg inj); 25-<50 kg 75 mg (as one 75 mg inj) w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing (every 4 wk), may be increased to 150 mg (as one 150 mg inj); <25 kg 75 mg (as one 75 mg inj) w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing (every 4 wk). Psoriatic arthritis, axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing. May be increased to 300 mg (as two 150 mg inj). Patients who are anti-TNFα inadequate responders or w/ concomitant moderate to severe plaque psoriasis 300 mg (as two 150 mg inj) w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing. Non-radiographic axial spondyloarthritis (nr-axSpA) 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing.
Contraindications
Severe hypersensitivity reactions.
Special Precautions
Discontinue immediately if anaphylactic or other serious allergic reaction occurs. Increased risk of infections. Patients w/ chronic or history of recurrent infection; active inflammatory bowel disease (eg, Crohn's disease & ulcerative colitis). Not to be given in patients w/ active TB. Consider anti-TB therapy prior to initiation in patients w/ latent TB. Not to be given concurrently w/ live vaccines. Pregnancy & lactation. Ped w/ plaque psoriasis <6 yr.
Adverse Reactions
Upper resp tract infections (nasopharyngitis, rhinitis). Oral herpes; rhinorrhoea; diarrhoea; urticaria.
Drug Interactions
Not to be given concurrently w/ live vaccines.
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) / Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations
ATC Classification
L04AC10 - secukinumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Scapho powd for soln for inj 150 mg/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in